Study: 'Wigofi' medicine to lose weight is useful for heart patients

A study showed that the medicine “wigofi” to treat obesity has a clear medical advantage in treating heart disease, in addition to weight loss, according to Novo Nordsk, Tuesday. The Danish company said in a statement that the weekly real estate injection reduces the risk of a serious injury of the heart and blood vessel, such as stroke, by 20% in people with weight gain or obesity and has a history of heart disease. The result was much better than the expectations of investors and analysts that the percentage would reach between 15% and 17% before the data was issued. The study, called ‘Celtic’, included 17,500 patients of 45 years or longer who have no history of diabetes. The role of food and sports and the study, described as ‘big’, has begun for almost five years to test whether the weekly injection has a medical advantage. In a statement, Martin Holst Lang, Executive Vice President Martin Holst Lang, said the results of the important experiment showed that Wigofi “has the ability to change the way to deal with obesity and treat it.” The company said it expects a request to approve the regulatory authorities on the weekly injection in the United States and the European Union. The results of the experiment are presented extensively at a scientific conference later in the year. The increasingly popular property has been a shift in the drug market for weight loss since the launch in the United States in June 2021, after attracting the attention of patients, investors and celebrities around the world and increasing Novo’s shares. The injection makes patients feel full for a longer period, and leads on average to 15% weight loss as it is related to changing diet and exercise. Also read: